Business Wire

CGTN: What Are Generations of Chinese Communists Striving For?

27.2.2021 18:36:00 EET | Business Wire | Press release

Share

The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century?

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/

"The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017.

"This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said.

Self-discipline, selflessness

In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless person is just like a lit candle giving all of its light to others."

He made the quotation at a symposium to commemorate the 120th birthday of late Premier Zhou Enlai (1898-1976), who joined the CPC in 1921, the year when the Party was founded.

"The lofty character of comrade Zhou Enlai, who selflessly pursued a just cause for the common good throughout his life, vividly reflects the traditional virtue of the Chinese nation and good moral qualities of the Chinese Communists, and will forever earn the respect of future generations," said Xi.

The comments "not only aimed to remember the noble character of Zhou who was self-disciplined, upright, honest and selfless, but also to encourage today's Communists to stay true to their original aspirations of the Party and shoulder their responsibilities," said Meng Man, a history professor at Minzu University of China.

New challenges, same aspiration

The number of the CPC members has exceeded 90 million, and China has become a much stronger nation than 100 years ago and the early decades of the People's Republic of China, but the aspiration of the Chinese Communists remains unchanged.

"To meet the people's desire for a happy life is our mission," Xi said when meeting the press after being elected as general secretary of the CPC Central Committee in November 2012.

Three years later, the communique of the fifth plenary session of the 18th CPC Central Committee underscored a people-centered development philosophy, stressing that China's development must be for the people and by the people, and its fruits shared among the people.

The notion was highlighted again in the CPC Central Committee's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035, which called for efforts to promote common prosperity for everyone.

China, in recent years, has been striving to build a moderately prosperous society in all respects and pursuing more balanced development. The CPC members have played leading roles in a nationwide poverty alleviation campaign to make sure nobody is left behind.

Over the past eight years, more than three million public sector officials were sent from cities and towns to villages to fight against poverty on the front lines and over 1,800 people died during the fight, Xi said on Thursday after announcing the country's "complete victory" in eradicating absolute poverty.

Putting people's life and health first, China has taken strict measures to battle the COVID-19 pandemic and effectively contained the virus, thanks to people from all walks of life for their efforts and sacrifices, particularly the CPC members.

More than 39 million CPC members fought the virus at the front line, and more than 13 million volunteered their services. Nearly 400 CPC members have defended others' lives and safety at the cost of their own.

When many parts of the country grappled with severe floods last summer, the Organization Department of the CPC Central Committee issued a circular to call on primary-level CPC organizations and members to fully play their role in flood control and relief work, urging them to ensure the safety of people's lives and property.

As China embarks on a new journey to fully build a modern socialist country, today's Chinese Communists – putting the people's and the nation's interests above those of themselves – are gearing up to take on their responsibilities as the older generations did.

Original article: https://news.cgtn.com/news/2021-02-27/What-are-generations-of-Chinese-Communists-striving-for--YdM2IOWzO8/index.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye